As of January 30, 2021, the Company is authorized to issue 8.0 million shares of $0.002 par value preferred stock and 992.0 million shares of $0.002 par value common stock. As of January 30, 2021, and February 1, 2020, no shares of preferred stock were outstanding.

In June 2019, the Company executed a funded research and development agreement with a business partner. In conjunction with the agreement, the Company issued a warrant to purchase 9.0 million of the Company's common shares, subject to certain vesting and exercise conditions.

For the years ended January 30, 2021 and February 1, 2020, the Company withheld approximately 3.1 million and 4.0 million shares, or $108.1 million and $98.3 million, of common stock, respectively, in settlement of employee tax withholding obligations due upon the vesting of restricted stock.

During fiscal 2021, the Company declared and paid cash dividends of $0.24 per common share, or $160.6 million, on the Company’s outstanding common stock. During fiscal 2020, the Company declared and paid cash dividends of $0.24 per common share, or $159.6 million, on the Company’s outstanding common stock.

On November 17, 2016, the Company announced that its Board of Directors authorized a $1.0 billion share repurchase plan. The newly authorized stock repurchase program replaced in its entirety the prior $3.25 billion stock repurchase program. On October 16, 2018, the Company announced that its Board of Directors authorized a $700 million addition to the balance of its existing share repurchase plan. The Company intends to effect share repurchases in accordance with the conditions of Rule 10b-18 under the Exchange Act, but may also make repurchases in the open market outside of Rule 10b-18 or in privately negotiated transactions. The share repurchase program will be subject to market conditions and other factors, and does not obligate the Company to repurchase any dollar amount or number of its common shares and the repurchase program may be extended, modified, suspended or discontinued at any time.

The Company repurchased 1.3 million of its common shares for $25.2 million , 14.5 million of its common shares for $364.3 million and 6.0 million of its common shares for $104.0 million in cash during fiscal 2021, 2020 and 2019, respectively. The repurchased shares were retired immediately after the repurchases were completed. The Company temporarily suspended the share repurchase program in late March 2020 to preserve cash during the COVID-19 pandemic and remains temporarily suspended in anticipation of the funding of the Company's acquisition of Inphi. As a result, the Company did not repurchase any shares subsequent to the first quarter of fiscal 2021. The Company records all repurchases, as well as investment purchases and sales, based on their trade date. As of January 30, 2021, a total of 308.1 million shares have been repurchased to date under the Company’s share repurchase program for a total $4.3 billion in cash and there was $564.5 million remaining available for future share repurchases.


	Shares Repurchased	Weighted- Average Price per Share		Amount Repurchased


Cumulative balance at February 3, 2018	286,365	$	13.19	$	3,776,557
Repurchase of common stock under the stock repurchase program	6,041	$	17.21	103,974
Cumulative balance at February 2, 2019	292,406	$	13.27	3,880,531
Repurchase of common stock under the stock repurchase program	14,486	$	25.15	364,272
Cumulative balance at February 1, 2020	306,892	$	13.83	4,244,803
Repurchase of common stock under the stock repurchase program	1,251	$	20.14	25,202
Cumulative balance at January 30, 2021	308,143	$	13.86	$	4,270,005